Markets:

Overview

News

Currencies

International

Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

17.40 -0.56 (-3.12%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

22 23 Next >

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

May 06, 2025

Via Benzinga

Which stocks are moving after the closing bell on Tuesday? ↗

May 06, 2025

The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

Via Chartmill

10 Health Care Stocks With Whale Alerts In Today's Session ↗

May 06, 2025

Via Benzinga

Earnings Scheduled For May 6, 2025 ↗

May 06, 2025

Via Benzinga

Earnings To Watch: Sarepta Therapeutics (SRPT) Reports Q1 Results Tomorrow

May 05, 2025

Biotech company Sarepta Therapeutics (NASDAQ:SRPT) will be reporting results tomorrow after market hours. Here’s what to look for.

Via StockStory

Topics Artificial Intelligence

1 of Wall Street’s Favorite Stock on Our Buy List and 2 to Approach with Caution

May 01, 2025

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,...

Via StockStory

Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost ↗

April 21, 2025

The new FDA commissioner had a few key ideas for the agency in an interview with Megyn Kelly.

Via Investor's Business Daily

Topics Government

Netflix To Rally More Than 55%? Here Are 10 Top Analyst Forecasts For Monday ↗

April 21, 2025

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

April 18, 2025

Via Benzinga

Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks

April 16, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with AbbVie...

Via StockStory

Topics Artificial Intelligence

Can Solid Biosciences Challenge Sarepta in the DMD Market?

April 08, 2025

Solid Biosciences' Duchenne muscular dystrophy (DMD) drug could provide superior outcomes compared to an already approved medication projected to make billions.

Via MarketBeat

3 Reasons to Avoid SRPT and 1 Stock to Buy Instead

April 08, 2025

The past six months haven’t been great for Sarepta Therapeutics. It just made a new 52-week low of $52, and shareholders have lost 56.6% of their capital. This may have investors wondering how to...

Via StockStory

Topics Supply Chain

4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street ↗

April 07, 2025

Via The Motley Fool

Sarepta Therapeutics Temporarily Halts Three Clinical Studies Of Elevidys: Retail Is Dull While Stock Drops ↗

April 04, 2025

H.C. Wainwright told investors in a research note that the clinical hold on key Elevidys trials in Europe heightens the uncertainty around the future of the franchise.

Via Stocktwits

Topics Government

Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death ↗

April 03, 2025

Sarepta and Roche paused Elevidys trials in the EU after a patient death. Analysts warn of potential sales declines as safety concerns impact market outlook.

Via Benzinga

Apple To $250? Here Are 10 Top Analyst Forecasts For Thursday ↗

April 03, 2025

Via Benzinga

Sarepta Plunges After EMA Puts Gene Therapy Studies On Hold Following Teen's Death ↗

April 03, 2025

The holds are temporary while the teenager's death is under investigation.

Via Investor's Business Daily

Topics Death

Deep Dive Into Sarepta Therapeutics Stock: Analyst Perspectives (18 Ratings) ↗

April 03, 2025

Via Benzinga

Q4 Earnings Outperformers: Amgen (NASDAQ:AMGN) And The Rest Of The Therapeutics Stocks

April 03, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with Amgen...

Via StockStory

Topics Artificial Intelligence

This Charles Schwab Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday ↗

April 02, 2025

Via Benzinga

Why Sarepta Therapeutics (SRPT) Stock Is Nosediving

March 31, 2025

Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 10.8% in the afternoon session after RBC analyst Brian Abrahams downgraded the stock from a Buy to a Hold rating and slashed the price...

Via StockStory

Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns ↗

March 31, 2025

Peter Marks heads up the department in charge of reviewing vaccines, genetic medicines and cell therapies.

Via Investor's Business Daily

Q4 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks

March 24, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Moderna (NASDAQ:MRNA) and the best and worst...

Via StockStory

Topics Artificial Intelligence

Is This Stock a Buy After a Massive 20% Drop in 1 Day? ↗

March 23, 2025

Via The Motley Fool

Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN)

March 21, 2025

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including BioMarin Pharmaceutical (NASDAQ:BMRN) and its...

Via StockStory

Topics Artificial Intelligence

Sarepta Therapeutics Stock Has A Nightmarish Week After DMD Patient Death, But Retail And Analysts Aren't Giving Up ↗

March 21, 2025

Jefferies acknowledged acute liver failure could signal a new safety risk but maintained that the high unmet need for DMD treatments supports the bull case.

Via Stocktwits

Nvidia, Meta, Sarepta, D-Wave, And Tesla: Why These 5 Stocks Are On Investors' Radars Today ↗

March 18, 2025

U.S. stock markets traded lower on Tuesday as investors awaited the Federal Reserve's interest rate decision. The Dow Jones Industrial Average slipped 0.6% to 41,581.31

Via Benzinga

Topics Economy Stocks

12 Analysts Have This To Say About Sarepta Therapeutics ↗

March 18, 2025

Via Benzinga

Wall Street Falters, Magnificent Seven Hit 7-Month Lows, Gold Rockets On Haven Demand: What's Driving Markets Tuesday? ↗

March 18, 2025

Volatility returned to Wall Street on Tuesday, with all major indexes trading in negative territory by midday in New York.

Via Benzinga

S&P 500 Down 1%; Sarepta Therapeutics Shares Plunge ↗

March 18, 2025

Via Benzinga

Topics Stocks

< Previous 1 2 3 4 5 6 7 8 9

...

22 23 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

Headline News about Sarepta Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today